Verici Dx PLC

Company Profile

• Business description

  Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

• Contact

  19 Stanwell Road
  Avon House
  Penarth
  CardiffCF64 2EZ
  GBR

  T: +44 2920710570

  https://www.vericidx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Diagnostics & Research

  Fiscal Year End

  31 December 2025

  Employees

  14